Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-07-23
DOI
10.3389/fonc.2019.00666
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
- (2019) Amelia McCartney et al. EUROPEAN JOURNAL OF CANCER
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- (2018) Jose Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
- (2018) Martina Bonechi et al. Oncotarget
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
- (2018) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- (2015) Barbie Taylor-Harding et al. Oncotarget
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy
- (2013) M. Bolayirli et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients
- (2012) Benjamin Nisman et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now